These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32342487)

  • 1. Theranostic drug test incorporating the bone-marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy.
    Dhami SPS; Tirincsi A; Baev D; Krawczyk J; Quinn J; Cahill MR; Zeugolis D; Szegezdi E
    Br J Haematol; 2020 Jun; 189(6):e254-e258. PubMed ID: 32342487
    [No Abstract]   [Full Text] [Related]  

  • 2. The bone marrow microenvironment - Home of the leukemic blasts.
    Shafat MS; Gnaneswaran B; Bowles KM; Rushworth SA
    Blood Rev; 2017 Sep; 31(5):277-286. PubMed ID: 28318761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
    Wang A; Zhong H
    Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.
    Houshmand M; Soleimani M; Atashi A; Saglio G; Abdollahi M; Nikougoftar Zarif M
    Tissue Eng Part C Methods; 2017 Feb; 23(2):72-85. PubMed ID: 28007011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the bone marrow microenvironment in acute leukemia.
    Karantanou C; Godavarthy PS; Krause DS
    Leuk Lymphoma; 2018 Nov; 59(11):2535-2545. PubMed ID: 29431560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
    Brenner AK; Andersson Tvedt TH; Bruserud Ø
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.
    Kuett A; Rieger C; Perathoner D; Herold T; Wagner M; Sironi S; Sotlar K; Horny HP; Deniffel C; Drolle H; Fiegl M
    Sci Rep; 2015 Dec; 5():18411. PubMed ID: 26674118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
    Piya S; Andreeff M; Borthakur G
    Autophagy; 2017 Jan; 13(1):214-215. PubMed ID: 27797294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
    O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
    Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment.
    Becker PS
    ScientificWorldJournal; 2012; 2012():856467. PubMed ID: 22346731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
    Ghiaur G; Levis M
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):681-692. PubMed ID: 28673395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting integrins in drug-resistant acute myeloid leukaemia.
    Ogana HA; Hurwitz S; Wei N; Lee E; Morris K; Parikh K; Kim YM
    Br J Pharmacol; 2024 Jan; 181(2):295-316. PubMed ID: 37258706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.
    Zeng Z; Liu W; Tsao T; Qiu Y; Zhao Y; Samudio I; Sarbassov DD; Kornblau SM; Baggerly KA; Kantarjian HM; Konopleva M; Andreeff M
    Haematologica; 2017 Sep; 102(9):1537-1548. PubMed ID: 28659338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia.
    Parker J; Hockney S; Blaschuk OW; Pal D
    Expert Rev Mol Med; 2023 May; 25():e16. PubMed ID: 37132370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Microenvironment in Resistance to Therapy in AML.
    Tabe Y; Konopleva M
    Curr Hematol Malig Rep; 2015 Jun; 10(2):96-103. PubMed ID: 25921386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Auer rods in neutrophils in bone marrow and peripheral blood in mixed phenotype acute leukaemia in a child.
    Kabbage S; Cupaiolo R; Rozen L; Demulder A
    Br J Haematol; 2019 Mar; 184(5):708. PubMed ID: 30407611
    [No Abstract]   [Full Text] [Related]  

  • 17. Stromal bone marrow fibroblasts and mesenchymal stem cells support acute myeloid leukaemia cells and promote therapy resistance.
    Miari KE; Williams MTS
    Br J Pharmacol; 2024 Jan; 181(2):216-237. PubMed ID: 36609915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia.
    Ladikou EE; Sivaloganathan H; Pepper A; Chevassut T
    Curr Oncol Rep; 2020 Feb; 22(3):27. PubMed ID: 32048054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow lipofuscin in a patient with acute myeloid leukaemia and extensive marrow necrosis.
    Giannoutsos I; Rosenfeld D
    Br J Haematol; 2007 Jul; 138(2):129. PubMed ID: 17489981
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the microenvironment in acute myeloid leukemia.
    Rashidi A; Uy GL
    Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.